Ignite Creation Date:
2024-05-05 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00330252
Status:
COMPLETED
Last Update Posted:
2016-05-13
First Post:
2006-05-25
Brief Title:
Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute